Nivolumab for relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT): Extended follow-up of the phase 2 single-arm CheckMate 205 study Meeting Abstract


Authors: Armand, P.; Engert, A.; Younes, A.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; Cohen, J. B.; De Boer, J. P.; Savage, K. J.; Kuruvilla, J.; TrnenĂ½, M.; Shipp, M. A.; Sacchi, M.; Ansell, Assm; Ansell, S. M.
Abstract Title: Nivolumab for relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT): Extended follow-up of the phase 2 single-arm CheckMate 205 study
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454842800096
PROVIDER: wos
DOI: 10.1182/blood-2018-99-112067
Notes: Meeting Abstract: 2897 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anas Younes
    320 Younes